In a phase I/II trial, 47% of patients with relapsed/refractory AML and TP53 abnormalities had a complete response to flotetuzumab with responders demonstrating a significantly higher baseline tumor inflammation score than nonresponders. This evidence concerns the gene TP53 and neoplasm.